Key points are not available for this paper at this time.
Niraparib inhibits ADPRylation and disrupts the nucleolar localization of DDX21 in endometrial and ovarian cancer cells. Inhibition of PARP1 catalytic activity in endometrial cancer cell lines (Ishikawa, HEC-1-A, KLE; A) and ovarian cancer cell lines (OVCAR3, OVCAR4, HCC5012; B) by niraparib promotes the redistribution of DDX21 from the nucleolus to the nucleoplasm but does not affect the nucleolar localization of NOP58 as assayed by immunofluorescent staining. C, Quantification of the results from experiments shown in A and B showing the proportion of cells that have disrupted nucleoplasmic localization of DDX21. Each bar represents the mean + SEM; n = 3 (endometrial), n = 6 (ovarian). Bars marked with asterisks are significantly different; Student t test; *, P P P D, ADPRylation (PAR) is inhibited in endometrial and ovarian cancer cells treated with niraparib. PARP1 and DDX21 protein expression levels are not affected by niraparib treatment as assayed by Western blotting. E, Quantification of PAR levels from experiments shown in D for endometrial and ovarian cancer cell lines with and without niraparib treatment. Each bar represents the mean + SEM; n = 3. Bars marked with asterisks are significantly different; Student t test; *, P P
Aljardali et al. (Thu,) studied this question.